Sharekhan

Alkem Laboratories Ltd

Wed 21/05/2025,15:52:18 | NSE : ALKEM

₹ 5374.00115.00 (2.19%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 5258.00

Previous Close

₹ 5259.00

Volume

209543

Mkt Cap ( Rs. Cr)

₹64254.23

High

₹ 5400.00

Low

₹ 5255.00

52 Week High

₹ 6439.90

52 Week Low

₹ 4407.05

Book Value Per Share

₹ 961.22

Dividend Yield

0.76

Face Value

₹ 2.00

What’s Your Call?

Collective community sentiment on Alkem Laboratories Ltd

Your Vote -

Buy

85.24%

Hold

13.49%

Sell

1.27%

85.24%

393 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

100%

Sell Order Quantity

0%

Bid Price

Qty

5374.00

11

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

11

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Alkem Laboratories Ltd' movement.

Call Price Open interest Strike Price Put Price Open interest

News

Media spotlight triggers stock stock attention, sentiment.

  • Alkem Laboratories - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    19 May 2025, 5:40PM With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we write to inform you that a confe
  • Alkem Laboratories - Analysts/Institutional Investor Meet/Con. Call Updates

    19 May 2025, 5:40PM Alkem Laboratories Limited has informed the Exchange about Schedule of meet
  • Alkem Laboratories - Board Meeting Intimation

    16 May 2025, 3:30PM ALKEM LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 29-May-2025 to consider and approve the Yearly Audited Financia
  • Alkem Laboratories - Board Meeting Intimation for Notice Of Meeting Of Board Of Directors Of The Company Scheduled To Be Held

    16 May 2025, 2:53PM Alkem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2025 ,inter alia, to consider a
  • Alkem Laboratories - General Updates

    15 May 2025, 6:28PM Alkem Laboratories Limited has informed the Exchange about a cyber security incident involving a US subsidiary of Enzene Biosciences Limited, a subsid
  • Alkem Laboratories - Announcement Under Regulation 30 (LODR) With Respect To A Cyber Security Incident Involving A US Subsidi

    15 May 2025, 6:23PM Enclosed herewith is the disclosure with respect to a cyber security incident involving a US subsidiary of Enzene Biosciences Limited, a subsidiary of
  • Alkem Laboratories - Update-Acquisition/Scheme/Sale/Disposal-XBRL

    23 Apr 2025, 2:03PM Alkem Laboratories Limited has informed the Exchange regarding Update-Acquisition/Scheme/Sale/Disposal-XBRL
  • Alkem Laboratories - General Updates

    23 Apr 2025, 1:56PM Alkem Laboratories Limited has informed the Exchange about an update related to the completion of acquisition by the Company, of 100% stake of Adroit
  • Alkem Laboratories - Announcement under Regulation 30 (LODR)-Updates on Acquisition

    23 Apr 2025, 1:52PM In continuation of our earlier intimations dated 07th February, 2025 and 28th March, 2025, we wish to inform you that today i.e. 23rd April, 2025, the
  • Alkem Laboratories - Update-Acquisition/Scheme/Sale/Disposal-XBRL

    17 Apr 2025, 12:29PM Alkem Laboratories Limited has informed the Exchange regarding Update-Acquisition/Scheme/Sale/Disposal-XBRL
  • Alkem Laboratories has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025

    17 Apr 2025, 5:20PM As of March 2025, 55.13% is owned by Indian Promoters and 44.87% by Public. <p align=justify> Institutional holds 28.82% (Insurance Companies 3.20%) a
  • Alkem Laboratories - General Updates

    16 Apr 2025, 11:52PM Alkem Laboratories Limited has informed the Exchange about an Update regarding the acquisition of 100% stake of Bombay Ortho Industries Private Limite
  • Alkem Laboratories - Disclosure under SEBI Takeover Regulations

    8 Apr 2025, 2:27PM Basudeo N. Singh has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial
  • Alkem Laboratories - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    31 Mar 2025, 1:35PM ALKEM LABORATORIES LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer
  • Alkem Laboratories - Retirement

    31 Mar 2025, 1:34PM Alkem Laboratories Limited has informed the Exchange about Retirement of Mr. Adil Billimoria as Senior Management Personnel of the Company with effect
  • Alkem Laboratories - Announcement Under Regulation 30 Of SEBI LODR- Regulatory Order

    28 Mar 2025, 5:58PM Pursuant to Regulation 30 of SEBI LODR Regulations, 2015, this is to inform you that the Company has received orders passed by the statutory authority
  • Alkem Laboratories - Action(s) initiated or orders passed

    28 Mar 2025, 5:57PM Alkem Laboratories Limited has informed the Exchange about Action(s) initiated or orders passed
  • Alkem Laboratories - Update-Acquisition/Scheme/Sale/Disposal-XBRL

    28 Mar 2025, 4:40PM Alkem Laboratories Limited has informed the Exchange regarding Update-Acquisition/Scheme/Sale/Disposal-XBRL
  • Alkem Laboratories - Announcement under Regulation 30 (LODR)-Updates on Acquisition

    28 Mar 2025, 4:32PM In continuation of our earlier intimation dated 07th February, 2025, we wish to inform you that today i.e. 28th March, 2025, a share purchase agreemen
  • Alkem Laboratories - General Updates

    28 Mar 2025, 4:31PM Alkem Laboratories Limited has informed the Exchange about General Updates
  • Alkem Laboratories - Disclosure under SEBI Takeover Regulations

    25 Mar 2025, 3:47PM Madhurima Singh has submitted to the Exchange a copy of Disclosures under Regulation 10(6)-Report to stock Exchange in respect of any acquisition made
  • Alkem Laboratories - Trading Window-XBRL

    24 Mar 2025, 1:08PM Alkem Laboratories Limited has informed the Exchange about Closure of Trading Window
  • Alkem Laboratories - Trading Window

    24 Mar 2025, 1:01PM Alkem Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulation
  • Alkem Laboratories - Analysts/Institutional Investor Meet/Con. Call Updates

    20 Mar 2025, 4:00PM Alkem Laboratories Limited has informed the Exchange about Schedule of meet
  • Alkem Laboratories - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    20 Mar 2025, 4:05PM Please find enclosed herewith the details of investor meeting scheduled to be held on 28th March, 2025.\r\n
  • Alkem Laboratories - Investor Presentation

    19 Mar 2025, 4:58PM Alkem Laboratories Limited has informed the Exchange about Investor Presentation
  • Alkem Laboratories - Announcement under Regulation 30 (LODR)-Investor Presentation

    19 Mar 2025, 4:57PM Please find enclosed herewith the presentation with respect to the Investor / Analyst Meeting scheduled to be held at 'HSBC Global Investment Summit 2
  • Alkem Laboratories - Analysts/Institutional Investor Meet/Con. Call Updates

    18 Mar 2025, 11:54AM Alkem Laboratories Limited has informed the Exchange about Schedule of meet
  • Alkem Laboratories - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    18 Mar 2025, 11:48AM Please find enclosed herewith the details of investors meetings scheduled to be held on 27th March, 2025 and 28th March, 2025.
  • Alkem Laboratories - Update-Acquisition/Scheme/Sale/Disposal-XBRL

    15 Mar 2025, 6:48PM Alkem Laboratories Limited has informed the Exchange regarding Update-Acquisition/Scheme/Sale/Disposal-XBRL
  • Alkem Laboratories - General Updates

    15 Mar 2025, 6:36PM Alkem Laboratories Limited has informed the Exchange about General Updates
  • Alkem Laboratories - Announcement under Regulation 30 (LODR)-Updates on Acquisition

    15 Mar 2025, 6:33PM In continuation of our earlier intimation dated 07th February, 2025, we wish to inform you that today i.e. 15th March, 2025, a share purchase and shar
  • Alkem Laboratories - Press Release

    13 Mar 2025, 4:16PM Alkem Laboratories Limited has informed the Exchange regarding a press release dated March 13, 2025, titled ""US FDA Inspection at Company s Bioequiva
  • Alkem Laboratories - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    13 Mar 2025, 4:15PM This is to inform you that US FDA had conducted a Bioresearch Monitoring (BIMO) inspection at the Company's Bioequivalence Centre located at Taloja, M
  • US FDA conducts bioresearch monitoring inspection at Alkem Laboratories' taloja facility

    13 Mar 2025, 4:13PM Alkem Laboratories has announced that the United States Food and Drug Administration (US FDA) conducted a Bioresearch Monitoring (BIMO) inspection at
  • Alkem Laboratories - Press Release

    12 Mar 2025, 10:05AM Alkem Laboratories Limited has informed the Exchange regarding a press release dated March 12, 2025, titled ""Alkem launches generic empagliflozin and
  • Alkem Laboratories - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    12 Mar 2025, 10:10AM This is to inform you that the Company launches generic empagliflozin and its combinations in India under the brand name \Empanorm\. A press release i
  • Alkem Laboratories - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    10 Mar 2025, 3:14PM ALKEM LABORATORIES LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer
  • Alkem Laboratories - Appointment

    10 Mar 2025, 1:59PM Alkem Laboratories Limited has informed the Exchange regarding appointment of Mr. Shirish Purushotham Ambulgekar as the Senior Management Personnel o
  • Alkem Laboratories - Analysts/Institutional Investor Meet/Con. Call Updates

    10 Mar 2025, 12:14PM Alkem Laboratories Limited has informed the Exchange about Schedule of meet
  • Alkem Laboratories - Announcement under Regulation 30 (LODR)-Change in Management

    10 Mar 2025, 1:55PM This is to inform you that Mr. Shirish Purushotham Ambulgekar has been appointed at the senior management position of the Company w.e.f. 10th March, 2
  • Alkem Laboratories - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    10 Mar 2025, 12:18PM Please find enclosed herewith the details of investor meetings scheduled to be held on 17th March, 2025, 18th March, 2025, 19th March, 2025, 24th Marc
  • Alkem Laboratories - Action(s) initiated or orders passed

    1 Mar 2025, 1:55PM Alkem Laboratories Limited has informed the Exchange about Action(s) initiated or orders passed
  • Alkem Laboratories - Action(s) initiated or orders passed

    1 Mar 2025, 9:15AM Alkem Laboratories Limited has informed the Exchange about Action(s) initiated or orders passed
  • Alkem Laboratories - Announcement Under Regulation 30 Of SEBI LODR- Regulatory Order

    1 Mar 2025, 2:02PM Pursuant to Regulation 30 of SEBI LODR Regulations, and further to our earlier intimation dated 28th December, 2024 this is to inform you that the Com
  • Alkem Laboratories - Announcement Under Regulation 30 Of SEBI LODR- Regulatory Order

    1 Mar 2025, 9:12AM Pursuant to Regulation 30 0f SEBI LODR Regulations, 2015, this is to inform that the Company has received an Order passed by the statutory authority
  • Alkem Laboratories - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    28 Feb 2025, 7:19PM ALKEM LABORATORIES LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer
  • Alkem Laboratories - Announcement under Regulation 30 (LODR)-Change in Management

    28 Feb 2025, 7:16PM This is to inform you that Mr. Sanjay Kumar Dipak has been appointed at the senior management position of the Company w.e.f 28th February, 2025.
  • Alkem Laboratories - Appointment

    28 Feb 2025, 7:15PM Alkem Laboratories Limited has informed the Exchange regarding Appointment of Sanjay Kumar Dipak as Senior Management Personnel of the company w.e.f.
  • Alkem Laboratories - Announcement Under Regulation 30 Of SEBI LODR- Regulatory Order

    28 Feb 2025, 6:11PM Pursuant to Regulation 30 of SEBI LODR Regulations, 2015, this is to inform you that the Company has received an Order passed by the statutory authori
  • Alkem Laboratories - Action(s) initiated or orders passed

    28 Feb 2025, 6:08PM Alkem Laboratories Limited has informed the Exchange about Action(s) initiated or orders passed
  • Alkem Laboratories - Announcement Under Regulation 30 Of SEBI LODR- Regulatory Order

    28 Feb 2025, 5:08PM Pursuant to Regulation 30 of SEBI LODR Regulations, 2015, this is to inform you that the Company has received an Order passed by the statutory authori
  • Alkem Laboratories - Action(s) initiated or orders passed

    28 Feb 2025, 5:04PM Alkem Laboratories Limited has informed the Exchange about Action(s) initiated or orders passed
  • Alkem Laboratories - Announcement Under Regulation 30 Of SEBI LODR- Regulatory Order

    28 Feb 2025, 3:26PM Pursuant to Regulation 30 of SEBI LODR Regulations, 2015, this is to inform you that the Company has received an Order passed by the statutory authori
  • Alkem Laboratories - Action(s) initiated or orders passed

    28 Feb 2025, 3:20PM Alkem Laboratories Limited has informed the Exchange about Action(s) initiated or orders passed
  • Alkem Laboratories - Announcement Under Regulation 30 Of SEBI LODR- Regulatory Order

    27 Feb 2025, 6:13PM Pursuant to Regulation 30 of SEBI LODR Regulations, 2015, this is to inform you that the Company has received Orders passed by the statutory authority
  • Alkem Laboratories - Action(s) initiated or orders passed

    27 Feb 2025, 6:11PM Alkem Laboratories Limited has informed the Exchange about Action(s) initiated or orders passed
  • Alkem Laboratories - Dislcosure letter under Regulation 11(5) of The Securities and Exchange Board of India (Substantial Ac

    25 Feb 2025, 9:47AM Samprada & Nanhamati Singh Family Trust has submitted a letter to Exchange on amendment to trust deed under Regulation 11(5) of The Securities and Ex
  • Alkem Labs launches Generic Empagliflozin & its combinations in India

    12 Mar 2025 , 11:02AM Empagliflozin is used in the treatment of type-2 diabetes mellitus, chronic kidney disease and heart failure
  • Alkem Laboratories

    5 Feb 2025 , 12:19PM The company introduces Kojiglo serum in India for managing facial hyperpigmentation.
  • Alkem Labs inks agreement to sell MP-based facility for Rs. 133.5 crore

    7 Jan 2025 , 12:18PM Alkem Labs to sell & transfer mfg unit in Pithampur, MP to Rubicon Research for Rs. 149 Cr
  • Alkem Laboratories to transfer trade generics business to Alkem Wellness

    10 Dec 2024 , 1:58PM Alkem Laboratories to transfer trade generics business to Alkem Wellness on slump sale basis
  • ALKEM signs a licensing agreement with Sonnet Bio

    10 Oct 2024 , 3:11PM Alkem Labs signs licensing agreement with Sonnet Bio to develop, mfg & commercialize 'SON-080'.
  • Alkem Laboratories

    29 Feb 2024 , 10:23AM The US FDA Inspected at Company’s API manufacturing facility located at Mandva and have issued an Establishment Inspection Report (EIR) for the said manufacturing facility. The Inspection has been classified as Voluntary Action Indicated (VAI) and was closed accordingly. (Positive)
  • Alkem Labs arm sells USA mfg unit to M/s New Mill Capital Holdings

    1 Jan 2024 , 1:04PM Alkem Labs arm sells St Louis, USA mfg unit for $7.9 m to M/s New Mill Capital Holdings
  • Alkem Laboratories

    4 Dec 2023 , 11:57AM The US FDA had conducted an inspection at Alkem Laboratories Limited's API manufacturing facility located at Mandva from 27th November, 2023 to 01st December, 2023. At the end of the inspection, the Company has received Form 483 with three (3) observations. There is no data integrity observation. (Neutral)
  • Biosergen, Alkem collaborate to develop anti-infective for severe fungal infections

    25 Sep 2023 , 10:57AM Alkem Labs signs license agreement with Biosergen AB for Polyene Macrolide Phase 2 & 3 trials in India
  • Alkem Labs, Zydus Life, Torrent Pharma, Dr. Reddy’s and Cipla

    21 Jul 2023 , 10:46AM The companies announced that NLCT Mumbai has approved the amalgamation of M/s Pharmasofttech Awacs Private Limited into M/s Pharmarack Technologies Private Limited., both of which are subsidiaries of M/s Aarogya Bharat Digital LLP (earlier known as M/s DigiHealth Technologies LLP), which in turn is a wholly owned subsidiary of their investee entity i.e., M/s ABCD Technologies LLP. The Companies own 6.45% interest in M/s ABCD Technologies LLP., each. Neutral read through.
  • Alkem Labs

    10 Apr 2023 , 10:37AM Alkem Laboratories Ltd. informed that the USFDA conducted a GMP and preapproval inspection at the company’s API manufacturing facility located at Ankaleshwar, Gujarat. At the end of the inspection, there were no observations that were issued. Positive for the stock. We do not have coverage in it.
  • Alkem Laboratories

    24 Feb 2023 , 10:07AM Enzene Biosciences, subsidiary of Alkem Laboratories said it has begun commercial supplies of adalimumab biosimilar used for treating autoimmune disease like rheumatoid arthritis and ankylosis spondylitis. This is Enzene's fourth biosimilar launch in the last eighteen months and the company believes that the first commercial launch using continuous manufacturing technology will help in reducing the cost of rheumatoid arthritis treatment, thereby boosting volumes for the product. Also, The USFDA concluded its inspection at Alkem’s manufacturing facility located at Indore and issued an Establishment Inspection Report (EIR) for the unit. It was inspected between July 1, 2022, to July 7, 2022. In response to Form 483 issued by the US FDA containing one observation, it had submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines. Positive read through for Alkem Labs. We do not have Alkem in coverage.
  • Alkem Laboratories

    22 Feb 2023 , 11:05AM India ratings affirmed Alkem Labs’ Commercial Papers’ rating to Ind A1+. The rating reflects Alkem’s leadership position and market share (MS) in the domestic acute therapy sub-segment, including anti-infective (rank: 1; MS: 9.6%, as per All Indian Origin Chemists and Distributors Ltd-Advanced Working, Action and Correction System; moving annual total September 2022), gastro-intestinal (rank: 3; MS: 5.7%), vitamins (rank: 3; MS: 5.5%), central nervous system (rank: 5; MS:2.5%), and pain management (rank: 6; MS: 3.6%) therapies. This was led by Alkem’s strong brand recall, consistent product launches and a wide physician coverage and prescription base, supported by a well-entrenched distribution network. However, concerns are that around 16% of Alkem’s domestic portfolio is under price control against Indian Pharmaceutical Market’s 13%, its Indore facility has form 483 issued with 1 observation in July 22. Alkem’s EBITDA margin declined to 14.4% in 9MFY23 (FY22: 19.3%), due to adverse product mix and a weak operating leverage. Ind-Ra notes that the company’s EBITDA margin remained higher at 21.9% in FY21, as against the historical average of 17%-18%, due to COVID-19-led saving on travelling and marketing expenses. Marginally positive to neutral read through for the stock.
  • Alkem Laboratories

    26 Dec 2022 , 12:25PM Alkem Laboratories is selling 8% stake in its subsidiary, Enzene Biosciences to Eight Roads Ventures India Healthcare IV LP, and F-Prime Capital Partners Life Sciences Fund VI LP for Rs. 161.48 Cr. The transaction is expected to be completed by January 2023. The funding will propel capacity expansions in India and US. Positive.
  • Alkem Laboratories

    16 Dec 2022 , 10:47AM Alkem Laboratories: As per media reports, Alkem Laboratories has got USFDA approval for Lurasidone Hydrochloride, which is used to treat symptoms of Schizophrenia. Our view: Neutral to marginally positive.
  • Alkem Laboratories

    18 Nov 2022 , 10:13AM Alkem Labs: The company gets US FDA nod for Vancomycin Hydrochloride. The drug is used to treat certain bacterial infection. Positive.
  • Alkem Labs gets Form 483 with two observations for St. Louis

    15 Sep 2022 , 1:34PM USFDA inspection at Alkem's manufacturing facility located at St. Louis, USA
  • Alkem Laboratories

    25 Jul 2022 , 10:07AM Alkem: Gets USFDA approval for Diclofenac Potassium for the US markets. The drug is indicated for treatment of or is used to relieve pain and swelling. Positive, though we do not have a coverage on the stock
  • Alkem Laboratories

    19 Jul 2022 , 10:27AM As per media reports, the company has received an approval from the USFDA for Erythromycin tablets for the US markets. These tablets are indicated for the treatment of bacterial infections – Positive
  • Alkem Laboratories

    8 Jul 2022 , 10:22AM Alkem Laboratories: USFDA had conducted a GMP and Pre-Approval inspection at the company’s Indore plant from 1 July 2022 to 7 July 2022. The inspection ended with a form 483 being issued with one observation for one of its ANDA which was filed from the plant. The observation from the USFDA is not relating to data integrity issue and the management is confident of submitting the response in the stipulated time frame. The receipt of form 483 is negative but the decline in stock prices factors in this and no data integrity issue provides respite.
  • Alkem Lab facility gets Form 483 with 3 observations from USFDA

    20 Jun 2022 , 10:52AM USFDA Inspection at Alkem's manufacturing facility located at St. Louis, USA
  • Alkem Laboratories

    20 Jun 2022 , 10:40AM Alkem Labs: The company’s plant based in St Louis USA was inspected by the USFDA from 6 th June to 7th June 2022 and the inspection ended with a Form 483 and three observations given to the company. The management intends to submit detailed response to the USFDA in stipulated time lines to close all the observations, However the receipt of Form 483 with three observations is a negative read thru
  • Alkem Laboratories

    4 Apr 2022 , 10:08AM Alkem Laboratories: The ISP Chile, had conducted an inspection of Alkem Laboratories’ manufacturing plant located at Daman between 28th March 2022 to 1st April 2022. The inspection has ended with no observations being issued relating to Good Manufacturing Practices. No observations received is positive, though we don’t have a coverage on the stock.
  • ALKEM signs a license agreement with Harvard University

    11 Feb 2022 , 12:16PM ALKEM licenses technology from Harvard University, aiming to treat ischemic injurv and vascular diseases
  • Alkem Labs board approves closure of operations

    20 Sep 2021 , 12:18PM Alkem Labs board nods closure of operations at Beta Block (Unit II) manufacturing facility located at Baddi
  • Alkem Lab launches Ibuprofen and Famotidine Tablets in US

    4 Aug 2021 , 12:46PM Alkem Laboratories introduces Ibuprofen and Famotidine Tablets (800 mg/26.6 mg) in the US, following an approval from the USFDA
  • Alkem launches Perampil at affordable prices

    10 Jun 2021 , 2:13PM Alkem introduces Perampil containing Perampanel at affordable prices to make the treatment accessible to the Indian population
  • Alkem Lab board nod commencement of commercial production/ operations

    9 Apr 2021 , 2:03PM Alkem Lab begins commercial production/ operations at Chakan manufacturing facility of Enzene Biosciences
  • Alkem Laboratories

    6 Apr 2021 , 9:37AM As per media reports gets USFDA approval for generic version of Azasan drugs – Azathioprine, used to prevent a patient's body from rejecting a transplanted kidney. Azathioprine is also used to treat symptoms of rheumatoid arthritis. The approval is positive for Alkem as it would add to the US sales of the company, which constitutes around 26% of FY20 sales
  • Alkem launches Brivaracetam in India under the brand name "Brivasure"

    15 Mar 2021 , 2:40PM Alkem makes epilepsy treatment more accessible & affordable with the launch of Brivasure
  • Alkem Laboratories

    24 Feb 2021 , 9:15AM As per media reports the company has received approval from the USFDA for two generic versions of antibiotic drugs - Omnicef and Suprax. The approvals are positive as they would add to the US sales growth.
  • Alkem Laboratories

    4 Jan 2021 , 9:58AM As per media reports, the company has received approval for generic of Gilenya. The drug is indicated for the treatment for Multiple sclerosis. The approval is positive as it would add to the US sales.
  • Alkem Laboratories

    8 Dec 2020 , 10:36AM As per media news, the company has received approval from the USFDA for Morphine Sulphate (15-30 mg), which is a painkiller. The approval is positive as it would widen the product offerings for the company.
  • Alkem Laboratories

    3 Dec 2020 , 9:38AM Alkem Labs: Has got USFDA approvals for Generic of Ranexa drug, which is an anti angina drug used to treat angina. Also it is used for heart problems and blood pressure control. The approval is positive as it would help grow the US sales.
  • Alkem Laboratories

    18 Nov 2020 , 11:16AM USFDA approval for Tacrolimus. The drug is indicated for treatment of Eczema and the approval is positive for the company as it would add to the US business growth.
  • Alkem Laboratories

    30 Oct 2020 , 10:14AM Alkem Labs: Gets US FDA nod for ADHD drug Amphetamine Sulfate. The drug is indicated is used to treat attention deficit hyperactivity disorder – ADHD. The approval is positive for the company as it would add to the US revenues of the company
  • Alkem Laboratories

    17 Jul 2020 , 10:59AM Gets USFDA approval for combination drug Brompheniramine Maleate, Dextromethorphan Hydrobromide & Pseudoephedrine Hydrochloride. The combination of these drugs is used to treat allergy & cold symptoms. The approval is positive as this would add to the US business growth.
  • Alkem Laboratories

    7 Jul 2020 , 10:13AM The company has received an approval from the USFDA for Deferasirox tablets which are oral iron chelator used to reduce chronic iron overload during blood transfusions. The approval is positive as it would improve the US business.
  • Alkem Laboratories

    22 May 2020 , 10:05AM As per media news, the company gets USFDA nod for Tolvaptan. The drug is indicated to treat low levels of sodium in the blood. Positive as this would add to the US business growth
  • Alkem Laboratories gets USFDA inspection report

    12 May 2020 , 2:34PM Closure of USFDA inspection at Alkem's manufacturing facility located at St. Louis USA
  • Alkem Laboratories

    1 Apr 2020 , 10:13AM As per media news gets US FDA approval for Azathioprine. The drug is used to prevent organ rejection in people who have received a kidney transplant and is also used for rheumatoid arthritis. Positive as this would widen the product offering in the US markets
  • Alkem Labs gains after USFDA concludes inspection

    13 Mar 2020 , 12:36PM USFDA concludes inspection at Baddi unit with zero observation
  • Alkem Laboratories

    13 Mar 2020 , 10:21AM As per media news the company has got an approval from the USFDA for Dabigatran Etexilate Mesylate. The drug is indicated to treat blood clots in veins of legs or lungs and to reduce the risk re-occurrence of the same. This is positive as it would enables the company to strengthen its US product portfolio.
  • Alkem Laboratories

    3 Feb 2020 , 12:38PM As per media reports, Alkem Laboratories has received a tentative approval from the US FDA for a generic version of Samsca tablet. This is positive for Alkem.
  • Alkem Laboratories

    27 Dec 2019 , 10:25AM As per media news, the company has received USFDA approval for Minocycline Hydrochloride tablet (45-135 mg). Minocycline hydrochloride tablets, USP are used to treat certain infections caused by bacteria. These include infections of the skin, respiratory tract, urinary tract and others; Positive read thru
  • Alkem Laboratories completes USFDA inspection with 4 observations

    26 Aug 2019 , 10:28AM USFDA Inspection at Alkem's manufacturing facilities located at St Louis, USA and Baddi, India
  • Alkem Labs falls on receiving 13 observations

    11 Apr 2018 , 1:52PM Alkem Laboratories slips by 3% at Rs1765, after receiving 13 observations from the USFDA
  • Alkem Lab receive 13 observations

    11 Apr 2018 , 11:40AM Negative read through for Alkem Lab.
  • Alkem Labs falls as USFDA issues 13 observations for Daman facility

    28 Mar 2018 , 2:17PM Alkem Labs slips over 11% at Rs1858, after the US drug regulator issued Form 483 with 13 observations for its Daman plant
  • Labs Daman facility is undergoing surprise USFDA audit

    21 Mar 2018 , 9:48AM Stock to remain in focus as Daman facility is very important facility for company as~6-8% of US sales come from this unit.
  • Alkem gets Establishment Inspection Report (EIR)

    10 Jan 2018 , 6:08PM Positive read through for Alkem as Alkem gets Establishment Inspection Report (EIR) for Baddi plant (which was issued form 483 with 2 observations during inspection in September 2017).
  • Alkem Labs get USFDA nod for drugs

    28 Dec 2017 , 9:23AM A positive read through for Alkem Labs as it receives USFDA approval for production of anti-dyslipidaemia combination drug
  • Alkem’s facility at St. Louis US clears USFDA inspection

    30 Oct 2017 , 10:20AM Positive news for Alkem as its facility at St. Louis US clears USFDA inspection (inspected between 23-27 October 2017) without any 483 observations
  • Alkem Labs falls on USFDA observations

    18 Sep 2017 , 11:02AM Alkem Labs slips over 3% to Rs1745, after receiving two observations from USFDA for its Baddi unit
  • Alkem labs clears USFDA inspection

    17 Jul 2017 , 11:54AM Alkem Labs announces that US drug regulator clears its Bioequivalence facility located at Taloja after the inspection
  • Alkem Labs gets green signal from USFDA for Itraconazole capsules

    15 Jun 2017 , 12:14PM Alkem Labs receives USFDA approval for Itraconazole capsules used to treat fungal infections

Key fundamentals

Evaluate the intrinsic value of Alkem Laboratories Ltd stock 

Name March-24 March-23 March-22 March-21 March-20
Assets 11511.84 10475.74 10989.18 8964.91 7489.82
Liabilities 11511.84 10475.74 10989.18 8964.91 7489.82
Equity 23.91 23.91 23.91 23.91 23.91
Gross Profit 1965.13 1376.95 1810.36 1948.93 1467.65
Net Profit 1747.15 1134.47 1541.25 1685.08 1264.42
Cash From Operating Activities 1686.56 1437.42 1299.34 1324.48 681.78
NPM(%) 17.92 12.52 17.45 23.34 18.93
Revenue 9747.72 9054.55 8829.81 7219.68 6677.08
Expenses 7782.59 7677.6 7019.45 5270.75 5209.43
ROE(%) 15.2 9.87 13.41 14.66 11

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
14 Feb 2025 37 1850 0.74 4916.05
09 Aug 2024 5 250 0.74 5262.45
16 Feb 2024 35 1750 0.74 4854.75
10 Aug 2023 10 500 0.74 3302.1
17 Feb 2023 25 1250 0.74 3020.2
17 Feb 2023 15 750 0.74 3009.25
08 Aug 2022 4 200 0.74 2905.75
10 Feb 2022 30 1500 0.74 3500.8
09 Aug 2021 5 250 0.74 2905
11 Feb 2021 25 1250 0.74 3049.6
10 Aug 2020 3 150 0.74 2394.55
13 Feb 2020 22 1100 0.74 2299.9
19 Aug 2019 8 400 0.74 1760.15
15 Feb 2019 8 400 0.74 1888.45
23 Aug 2018 7 350 0.74 1983.2
16 Feb 2018 6 300 0.74 2198.75
31 Aug 2017 9 450 0.74 1872.4
23 Nov 2016 6 300 0.74 1643.55
18 Mar 2016 9.7 485 0.74 1345.75

Peers

Other companies within the same industry or sector that are comparable to Alkem Laboratories Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 810.15 -0.84 26.88 3002.44 301.39 0.62
Lotus Eye Hospital and Institute Ltd 74.06 0.78 308.58 10940.52 14.01 0.68
Vaishali Pharma Ltd 12.85 -1.15 428.33 5639.16 2.76 0.00
Astec Lifesciences Ltd 701.25 -1.59 0.00 10315.96 -687.11 0.00

Company Info

The Company was incorporated as a private limited company `Alkem Laboratories Private Limited' on August 8,1973 at Patna under the Companies Act, 1956 and subsequently became a deemed public limited company under section 43A(2) of Companies Act, 1956 on October 26, 1988. Pursuant to the Company passing a resolution under section 21 of Companies Act, 1956 and upon issuance of a fresh certificate of incorporation consequent on change of name dated August 21, 2001, the name of the Company was changed to `Alkem Laboratories Limited' with effect from October 26, 1988. the registered office was originally located at `Exhibition Road, Patna - 800 001, Bihar, India'. the Company filed Company Petition No. 356(17)/ ERB/ 2007 before the Company Law Board, Eastern Region Bench at Kolkata for shifting the registered office of the Company from the State of Bihar to the State of Maharashtra, as approved by a special resolution at its extra-ordinary general meeting held on January 29, 2007. The Company Law Board, Eastern Region Bench at Kolkata passed an order dated July 30, 2007 whereby it confirmed the alteration of the situation clause in the Memorandum of Association, from the State of Bihar to the State of Maharashtra. Pursuant to the order, the registered office of the Company was shifted to `Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai - 400 013, Maharashtra, India' with effect from August 2, 2007. Major Events : 1973 -Incorporation of the Company. 1978 -the Company established its first plant at Taloja, Maharashtra. 1988 -the Company became a deemed public limited company. 1992 -the Company established its manufacturing facility in Mandwa, Maharashtra. This facility was converted into an API facility in 2005. 1998 -the Company established its Kachigam manufacturing facility in Gujarat. 2001 -Startronic Pharmachem Private Limited and Indo Propkem amalgamated with the Company. 2002 -the Company established its Amaliya manufacturing facility in Gujarat. 2003 -the Company set up its research and development facility at Taloja, Maharashtra. 2005 -the Company established its manufacturing facility in Baddi, Himachal Pradesh. 2006 -the anti-infective drug Taxim became the first drug in the Indian pharmaceutical industry to cross 1,000 million in terms of domestic sales in India (Source: IMS Research) 2007 -the Company established its manufacturing facility in Kumrek, Sikkim. -the Company filed its first ANDA in the United States for the drug, Amlodipine. -the Company shifted its Registered Office from Patna, Bihar to Mumbai, Maharashtra. 2009 -the Company acquired Pharmacor, a generic pharma company in Australia. 2010 -the Company acquired The PharmaNetwork, LLC, the holding company of Ascend Laboratories LLC. 2011 -the Company acquired Enzene Bio sciences Limited. 2012 -the Company acquired an API manufacturing facility in the United States. 2014 -the Company acquired the Clindac. 2015 -the Company acquired a formulation manufacturing facility in the United States. Awards and achievements: 2002 -the Company was awarded the Pharma Business and Technology Excellence Award in 2002 as 'India's Most Esteemed Pharmaceutical Company' 2004 -the product Taxim was awarded the Pharma Business and Technology Excellence Award for successful brand in 2004 2005 -the Company was awarded the Overall Performance Award for Group B at the 5th Express Pharma Awards in 2005 2009 -the Company received a certificate of appreciation for outstanding export performance in the category of formulations by the Pharmaceuticals Export Promotion Council of India, supported by Ministry of Commerce and Industry, GOI -the Company received the certificate of appreciation in the category of `Formulation Experts' by the Pharmaceuticals Export Promotion Council of India, supported by Ministry of Commerce and Industry, GOI 2013 -the Company was awarded the India's most admired pharma company award for 2013 at the 6th Annual Pharmaceutical Leadership Summit in 2013 2014 -the Product `Clavam' was awarded as the ` Brand of the Year' at the AWACS Award, 2014 2016 -Alkem's Mandva Plant successfully obtains the Establishment Inspection Report from the US FDA -Alkem receives EIR from the US FDA for its Daman formulation facility 2017 -Marketing alliance with Haw Par to excusively market, sell and distribute Tiger Balam range of Product in India. -Direct consumer marketing for pregakem and Livoerb -Alkem received the Best Stand-out IR award 2017 by IR Society India in association with KPMG and Bloomberg 2018 -Revenue from the US market Crossed USD 200 mn in annual sales -Brand 'Clavam' receiving Brand of the Year 2018 at AWACS AWARDS FOR Marketing Excellence 2019 -Crossed the reenue milestone of USD 1 billion -Express Pharma Excellence Award at Pharma CXO Sumit 2019 -Alkem Laboratories takes over undertaking from Cachet Pharmaceuticals 2020 -Launch of Favipiravir in India under the brand name 'Alfluenza' -CIO Conclave and Awards 2020 'In the category Best IT team of the Year' 2021 -Launch of Ibuprofen and Famotidine Tablets in the United States -Launch of Perampanel Tablets in India unde the brand name 'Perampil' -Alkem Parners with Tata Memorial Hospital -Launch of Brivaracetam in India under the Brand name 'Brivasure' -India's Best Wrokplaces in Biotechnology & Pharmaceutical Industry for the second consecutive year 2022 -Alkem signs license agreement with Harvard University's Office of Technology Development. 2023 -The Company has informed that ,the Company and Biosergen AB have entered into a co-development and license agreement for development and commercialization of Biosergen's novel polyene macrolide antifungal product BSG005 for the treatment of severe invasive fungal disease. - The NCLT has approved the Scheme of Amalgamation for merger of M/s. Pharmasofttech Awacs Pvt. Ltd. into M/s. Pharmarack Technologies Pvt. Ltd. Both these Companies are subsidiaries of M/s Aarogya Bharat Digital LLP (earlier known as M/s. DigiHealth Technologies LLP). which in turn is a wholly-owned subsidiary of our investee entity i.e. M/s. ABCD Technologies LLP.

The Company was incorporated as a private limited company `Alkem Laboratories Private Limited' on August 8,1973 at Patna under the Companies Act, 1956 and subsequently became a deemed public limited company under section 43A(2) of Companies Act, 1956 on October 26, 1988. Pursuant to the Company passing a resolution under section 21 of Companies Act, 1956 and upon issuance of a fresh certificate of incorporation consequent on change of name dated August 21, 2001, the name of the Company was changed to `Alkem Laboratories Limited' with effect from October 26, 1988. the registered office was originally located at `Exhibition Road, Patna - 800 001, Bihar, India'. the Company filed Company Petition No. 356(17)/ ERB/ 2007 before the Company Law Board, Eastern Region Bench at Kolkata for shifting the registered office of the Company from the State of Bihar to the State of Maharashtra, as approved by a special resolution at its extra-ordinary general meeting held on January 29, 2007. The Company Law Board, Eastern Region Bench at Kolkata passed an order dated July 30, 2007 whereby it confirmed the alteration of the situation clause in the Memorandum of Association, from the State of Bihar to the State of Maharashtra. Pursuant to the order, the registered office of the Company was shifted to `Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai - 400 013, Maharashtra, India' with effect from August 2, 2007. Major Events : 1973 -Incorporation of the Company. 1978 -the Company established its first plant at Taloja, Maharashtra. 1988 -the Company became a deemed public limited company. 1992 -the Company established its manufacturing facility in Mandwa, Maharashtra. This facility was converted into an API facility in 2005. 1998 -the Company established its Kachigam manufacturing facility in Gujarat. 2001 -Startronic Pharmachem Private Limited and Indo Propkem amalgamated with the Company. 2002 -the Company established its Amaliya manufacturing facility in Gujarat. 2003 -the Company set up its research and development facility at Taloja, Maharashtra. 2005 -the Company established its manufacturing facility in Baddi, Himachal Pradesh. 2006 -the anti-infective drug Taxim became the first drug in the Indian pharmaceutical industry to cross 1,000 million in terms of domestic sales in India (Source: IMS Research) 2007 -the Company established its manufacturing facility in Kumrek, Sikkim. -the Company filed its first ANDA in the United States for the drug, Amlodipine. -the Company shifted its Registered Office from Patna, Bihar to Mumbai, Maharashtra. 2009 -the Company acquired Pharmacor, a generic pharma company in Australia. 2010 -the Company acquired The PharmaNetwork, LLC, the holding company of Ascend Laboratories LLC. 2011 -the Company acquired Enzene Bio sciences Limited. 2012 -the Company acquired an API manufacturing facility in the United States. 2014 -the Company acquired the Clindac. 2015 -the Company acquired a formulation manufacturing facility in the United States. Awards and achievements: 2002 -the Company was awarded the Pharma Business and Technology Excellence Award in 2002 as 'India's Most Esteemed Pharmaceutical Company' 2004 -the product Taxim was awarded the Pharma Business and Technology Excellence Award for successful brand in 2004 2005 -the Company was awarded the Overall Performance Award for Group B at the 5th Express Pharma Awards in 2005 2009 -the Company received a certificate of appreciation for outstanding export performance in the category of formulations by the Pharmaceuticals Export Promotion Council of India, supported by Ministry of Commerce and Industry, GOI -the Company received the certificate of appreciation in the category of `Formulation Experts' by the Pharmaceuticals Export Promotion Council of India, supported by Ministry of Commerce and Industry, GOI 2013 -the Company was awarded the India's most admired pharma company award for 2013 at the 6th Annual Pharmaceutical Leadership Summit in 2013 2014 -the Product `Clavam' was awarded as the ` Brand of the Year' at the AWACS Award, 2014 2016 -Alkem's Mandva Plant successfully obtains the Establishment Inspection Report from the US FDA -Alkem receives EIR from the US FDA for its Daman formulation facility 2017 -Marketing alliance with Haw Par to excusively market, sell and distribute Tiger Balam range of Product in India. -Direct consumer marketing for pregakem and Livoerb -Alkem received the Best Stand-out IR award 2017 by IR Society India in association with KPMG and Bloomberg 2018 -Revenue from the US market Crossed USD 200 mn in annual sales -Brand 'Clavam' receiving Brand of the Year 2018 at AWACS AWARDS FOR Marketing Excellence 2019 -Crossed the reenue milestone of USD 1 billion -Express Pharma Excellence Award at Pharma CXO Sumit 2019 -Alkem Laboratories takes over undertaking from Cachet Pharmaceuticals 2020 -Launch of Favipiravir in India under the brand name 'Alfluenza' -CIO Conclave and Awards 2020 'In the category Best IT team of the Year' 2021 -Launch of Ibuprofen and Famotidine Tablets in the United States -Launch of Perampanel Tablets in India unde the brand name 'Perampil' -Alkem Parners with Tata Memorial Hospital -Launch of Brivaracetam in India under the Brand name 'Brivasure' -India's Best Wrokplaces in Biotechnology & Pharmaceutical Industry for the second consecutive year 2022 -Alkem signs license agreement with Harvard University's Office of Technology Development. 2023 -The Company has informed that ,the Company and Biosergen AB have entered into a co-development and license agreement for development and commercialization of Biosergen's novel polyene macrolide antifungal product BSG005 for the treatment of severe invasive fungal disease. - The NCLT has approved the Scheme of Amalgamation for merger of M/s. Pharmasofttech Awacs Pvt. Ltd. into M/s. Pharmarack Technologies Pvt. Ltd. Both these Companies are subsidiaries of M/s Aarogya Bharat Digital LLP (earlier known as M/s. DigiHealth Technologies LLP). which in turn is a wholly-owned subsidiary of our investee entity i.e. M/s. ABCD Technologies LLP.

Read More

Parent Organisation

Alkem Laboratories Ltd.

Founded

08/08/1973

Managing Director

Mr.Sandeep Singh

NSE Symbol

ALKEMEQ

FAQ

The current price of Alkem Laboratories Ltd is ₹ 5374.00.

The 52-week high for Alkem Laboratories Ltd is ₹ 5400.00 and the 52-week low is ₹ 5255.00.

The market capitalization of Alkem Laboratories Ltd is currently ₹ 64254.23. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Alkem Laboratories Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Alkem Laboratories Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Alkem Laboratories Ltd shares.

The CEO of Alkem Laboratories Ltd is Mr.Sandeep Singh, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT